65 results
8-K
EX-10.1
CNSP
Cns Pharmaceuticals Inc
14 Jun 24
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
5:25pm
(or such shorter period as the Company was required by law or regulation to file such materials) (the foregoing materials, including the exhibits thereto … , contaminants, petroleum products or other hazardous or toxic substances, chemicals or materials (“Hazardous Substances”) by, due to, on behalf of, or caused
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
12 Apr 24
Regulation FD Disclosure
6:37pm
Exhibit 99.1
INVESTOR PRESENTATION April 2024 www.CNSPharma.com NASDAQ: CNSP
NASDAQ: CNSP This presentation incorporates information from materials
8-K
g6xqiq4vnyb6k4
21 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
EX-1.1
joew1nq40qtctg8tx
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
nhw 4zsthvoizx
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
424B4
ks6b8e
31 Jan 24
Prospectus supplement with pricing info
4:27pm
8-K
EX-10.1
g7q0fw dd
17 Oct 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.1
g2svwnamyabz7jnxyr
1 Dec 22
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
5:19pm